文献速递儿科与产科急症

氨甲环酸预防阴道分娩后失血

Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery.
PubMed 文献 · N Engl J Med · 2018-01-01
一句话结论在预防性使用缩宫素的阴道分娩产妇中,产后静脉给予氨甲环酸1 g未显著降低产后出血(≥500 ml)发生率(8.1% vs 9.8%,RR 0.83,95%CI 0.68–1.01,P=0.07)。

该多中心、双盲、随机对照试验纳入计划阴道分娩单胎活产、孕周≥35周的产妇,在胎儿娩出后预防性使用缩宫素的基础上,随机给予氨甲环酸1 g静脉注射或安慰剂。随机化4079例,其中3891例经阴道分娩。主要结局产后出血(失血量≥500 ml,收集袋测量)在氨甲环酸组156/1921例(8.1%)、安慰剂组188/1918例(9.8%),差异未达统计学显著(RR 0.83,95%CI 0.68–1.01,P=0.07)。氨甲环酸组医疗提供者评估的临床显著产后出血率更低(7.8% vs 10.4%,RR 0.74,95%CI 0.61–0.91,P=0.004;事后多重比较校正后P=0.04),额外使用宫缩剂更少(7.2% vs 9.7%,RR 0.75,95%CI 0.61–0.92,P=0.006;校正后P=0.04)。产后3个月内血栓栓塞事件两组无显著差异(0.1% vs 0.2%,RR 0.25,95%CI 0.03–2.24)。

要点

  • 在预防性缩宫素基础上,阴道分娩后静脉给予氨甲环酸1 g未显著降低主要结局产后出血(≥500 ml)发生率(8.1% vs 9.8%,RR 0.83,95%CI 0.68–1.01,P=0.07)。
  • 氨甲环酸组医疗提供者评估的临床显著产后出血率低于安慰剂组(7.8% vs 10.4%,RR 0.74,95%CI 0.61–0.91,P=0.004;事后多重比较校正后P=0.04)。
  • 氨甲环酸组额外使用宫缩剂的比例低于安慰剂组(7.2% vs 9.7%,RR 0.75,95%CI 0.61–0.92,P=0.006;校正后P=0.04)。
  • 产后3个月内血栓栓塞事件发生率两组无显著差异(氨甲环酸组0.1% vs 安慰剂组0.2%,RR 0.25,95%CI 0.03–2.24)。
  • 其他次要结局两组无显著差异。

适用人群与场景

  • 计划阴道分娩、单胎活产、孕周≥35周的临产产妇。

诊断标准与关键阈值

  • 产后出血定义为主要结局:使用收集袋测量的失血量≥500 ml。

处置流程与药物剂量

  • 胎儿娩出后,在预防性使用缩宫素的基础上,静脉给予氨甲环酸1 g或安慰剂。

研究设计与关键结果

  • 多中心、双盲、随机对照试验,随机化4079例,其中3891例经阴道分娩。
  • 主要结局产后出血(≥500 ml)发生率:氨甲环酸组156/1921例(8.1%)vs 安慰剂组188/1918例(9.8%),RR 0.83(95%CI 0.68–1.01),P=0.07,未达统计学显著。
  • 医疗提供者评估的临床显著产后出血率:氨甲环酸组7.8% vs 安慰剂组10.4%,RR 0.74(95%CI 0.61–0.91),P=0.004,事后多重比较校正后P=0.04。
  • 额外使用宫缩剂比例:氨甲环酸组7.2% vs 安慰剂组9.7%,RR 0.75(95%CI 0.61–0.92),P=0.006,校正后P=0.04。
  • 产后3个月内血栓栓塞事件发生率:氨甲环酸组0.1% vs 安慰剂组0.2%,RR 0.25(95%CI 0.03–2.24),两组无显著差异。
  • 其他次要结局两组无显著差异。

证据类型、等级与局限

  • 证据类型:多中心、双盲、随机对照试验(TRAAP,NCT02302456)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于计划阴道分娩、孕周≥35周且已预防性使用缩宫素的产妇,阴道分娩后静脉给予氨甲环酸1 g未能显著降低失血量≥500 ml的产后出血发生率。
  • 该干预与医疗提供者评估的临床显著产后出血率降低及额外宫缩剂使用减少相关,但主要结局未达统计学显著。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The use of tranexamic acid reduces mortality due to postpartum hemorrhage. We investigated whether the prophylactic administration of tranexamic acid in addition to prophylactic oxytocin in women with vaginal delivery would decrease the incidence of postpartum hemorrhage.

METHODS: In a multicenter, double-blind, randomized, controlled trial, we randomly assigned women in labor who had a planned vaginal delivery of a singleton live fetus at 35 or more weeks of gestation to receive 1 g of tranexamic acid or placebo, administered intravenously, in addition to prophylactic oxytocin after delivery. The primary outcome was postpartum hemorrhage, defined as blood loss of at least 500 ml, measured with a collector bag.

RESULTS: Of the 4079 women who underwent randomization, 3891 had a vaginal delivery. The primary outcome occurred in 156 of 1921 women (8.1%) in the tranexamic acid group and in 188 of 1918 (9.8%) in the placebo group (relative risk, 0.83; 95% confidence interval [CI], 0.68 to 1.01; P=0.07). Women in the tranexamic acid group had a lower rate of provider-assessed clinically significant postpartum hemorrhage than those in the placebo group (7.8% vs. 10.4%; relative risk, 0.74; 95% CI, 0.61 to 0.91; P=0.004; P=0.04 after adjustment for multiple comparisons post hoc) and also received additional uterotonic agents less often (7.2% vs. 9.7%; relative risk, 0.75; 95% CI, 0.61 to 0.92; P=0.006; adjusted P=0.04). Other secondary outcomes did not differ significantly between the two groups. The incidence of thromboembolic events in the 3 months after delivery did not differ significantly between the tranexamic acid group and the placebo group (0.1% and 0.2%, respectively; relative risk, 0.25; 95% CI, 0.03 to 2.24).

CONCLUSIONS: Among women with vaginal delivery who received prophylactic oxytocin, the use of tranexamic acid did not result in a rate of postpartum hemorrhage of at least 500 ml that was significantly lower than the rate with placebo. (Funded by the French Ministry of Health; TRAAP ClinicalTrials.gov number, NCT02302456 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Sentilhes L, Winer N, Azria E, et al. Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery. N Engl J Med. 2018. PMID: 30134136. doi:10.1056/NEJMoa1800942

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。